Oppenheimer Reiterates Outperform on Cartesian Therapeutics, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler has reiterated an Outperform rating on Cartesian Therapeutics (NASDAQ:RNAC) and maintained a $50 price target.
June 24, 2024 | 5:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Matthew Biegler has reiterated an Outperform rating on Cartesian Therapeutics (NASDAQ:RNAC) and maintained a $50 price target.
The reiteration of an Outperform rating and the maintenance of a $50 price target by a reputable analyst from Oppenheimer is likely to positively influence investor sentiment and could lead to a short-term increase in RNAC's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100